Infinant Health

Executive Summary

Infinant Health is a microbiome-focused biotechnology company pioneering interventions that target the infant gut microbiome to improve lifelong health. Leveraging its proprietary Bifidobacterium longum subsp. infantis (B. infantis) EVC001 strain, the company develops nutritional and therapeutic products designed to work synergistically with breast milk. By restoring the beneficial bacteria that are often missing in modern infants, Infinant Health aims to reduce the risk of immune-mediated diseases such as allergies, asthma, and autoimmune conditions. Founded in 2018 and based in Davis, California, the company operates at the intersection of maternal-infant nutrition and microbiome therapeutics, addressing a critical window for foundational health establishment. The company’s lead candidate, EVivo (EVC001), has shown promise in clinical studies for reducing gut inflammation and establishing a healthy microbiome. Infinant Health is progressing toward regulatory approvals and commercial partnerships to bring its products to market. With a strong scientific foundation and growing awareness of the infant microbiome's role in long-term health, the company is well-positioned to capture value in the emerging microbiome therapeutics space. However, as a private, early-stage company, it faces significant clinical and commercial risks. The conviction score reflects cautious optimism based on the compelling science and near-term milestones.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 2 clinical trial results for EVC001 in reducing atopic dermatitis risk65% success
• Q4 2026FDA designation (e.g., Breakthrough Therapy or Orphan Drug) for lead candidate40% success
• TBDStrategic partnership with major infant formula manufacturer for distribution50% success